Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

COVID-19 GPH|Home|PHGKB Last data update: Feb 05, 2023 . (Total: 43376 Documents since 2020)

Last Posted: Feb-05-2023 11:11:55
spot light Spotlight

Unlocking life-threatening COVID-19 through two types of inborn errors of type I IFNs.
Jean-Laurent Casanova et al. The Journal of clinical investigation 2023 1 (3)

Since 2003, rare inborn errors of human type I IFN immunity have been discovered, each underlying a few severe viral illnesses. Autoantibodies neutralizing type I IFNs due to rare inborn errors of autoimmune regulator (AIRE)–driven T cell tolerance were discovered in 2006, but not initially linked to any viral disease. These two lines of clinical investigation converged in 2020, with the discovery that inherited and/or autoimmune deficiencies of type I IFN immunity accounted for approximately 15%–20% of cases of critical COVID-19 pneumonia in unvaccinated individuals.

Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.
Yuchen Wei et al. JAMA network open 2023 2 (2) e2254777

Does vaccine effectiveness against hospitalization and mortality due to the SARS-CoV-2 Omicron variant change over time? In this case-control study with 164?151 participants, the CoronaVac and BNT162b2 vaccines were generally estimated to be effective against severe outcomes due to SARS-CoV-2 Omicron infection, but protection among older individuals was more likely to wane 6 months after the second dose.

How quickly does COVID immunity fade? What scientists know.
Cassandra Willyard et al. Nature 2023 2

Three years into the pandemic, the immune systems of the vast majority of humans have learnt to recognize SARS-CoV-2 through vaccination, infection or, in many cases, both. But just how quickly do these types of immunity fade? New evidence suggests that ‘hybrid’ immunity, the result of both vaccination and a bout of COVID-19, can provide partial protection against reinfection for at least eight months. It also offers greater than 95% protection against severe disease or hospitalization for between six months and a year after an infection or vaccination, according to estimates from a meta-analysis. Immunity acquired by booster vaccination alone seems to fade somewhat faster.

Global generalisability of AI-driven COVID-19 vaccination policies: a cross-sectional observational study
R Awasthi et al, MEDRXIV, February 2, 2023

We found 16 important predictors of vaccine uptake using the Bayesian network and Markov Blanket approach. We found that the trust of the central government (Log-Odds 0.55[0.25, 0.84] (p= 0.0002)), Vaccination restriction for national and international travel (Log-Odds 0.4[0.14, 0.65] (p= 0.0034)) as the key determinants of Vaccine uptake.

news Latest News and Publications
Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model.
Karampitsakos Theodoros, et al. Frontiers in medicine 2023 0 0. 1083264

New Added Today

Identification and development of a five-gene signature to improve the prediction of mechanical ventilator-free days for patients with COVID-19.
Ni J-X, et al. European review for medical and pharmacological sciences 2023 0 0. (2) 805-817

New Added Today

Mutational analysis of the spike protein of SARS-COV-2 isolates revealed atomistic features responsible for higher binding and infectivity.
Hanifa Muhammad, et al. Frontiers in cell and developmental biology 2023 0 0. 940863

New Added Today

Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant.
Uriu Keiya, et al. The Lancet. Infectious diseases 2023 0 0.

New Added Today

COVID-19 booster vaccination coverage among adults, children and adolescents and reasons for non-receipt, United States.
Nguyen Kimberly H, et al. American journal of infection control 2023 0 0.

New Added Today

Emerging role of microRNAs and long non-coding RNAs in COVID-19 with implications to therapeutics.
Arman Kaifee, et al. Gene 2023 0 0. 147232

New Added Today

An overview of current accomplishments and gaps of COVID-19 vaccine platforms and considerations for next generation vaccines.
Kale Akanksha, et al. Journal of pharmaceutical sciences 2023 0 0.

New Added Today

A Comparative study on epidemiological characteristics, transmissibility, and pathogenicity of three COVID-19 outbreaks caused by different variants.
Liu Chan, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2023 0 0.

New Added Today

Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination.
Varea-Jiménez Elena, et al. Enfermedades infecciosas y microbiologia clinica (English ed.) 2023 0 0.

New Added Today

APOE4: A Culprit for the Vulnerability of COVID-19 in Alzheimer's Patients.
Goyal Ahsas, et al. Current neurovascular research 2023 0 0.

New Added Today

All Latest

About COVID-19 GPH

COVID-19 GPH is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that capture emerging discoveries and applications of genomics, molecular and other precision medicine and precision public health tools in the investigation and control of COVID-19. Contents include PubMed records via an automated pubmed search algorithm, preprint records from NIH iCite, the relevant information from many media sources picked by experts, and linkages to contents from our curated PHGKB databases.

Site Citation:
Wei Yu, et al. COVID-19 GPH: tracking the contribution of genomics and precision health to the COVID-19 pandemic response. BMC Infectious Diseases (2022) 22:402.

update trend

Sign up Email Alert


All Records43376
Genomics Precision Health31681
Non-Genomics Precision Health11695

Publication Categories Brand

Variants 12641
Vaccines 10763
Treatment 10013
Mechanism 9906
Diagnosis 7284
Prevention 5205
Surveillance 3815
Forecasting 3377
Transmission 2072
Health Equity 1125

Publication Types

PubMed Records32994
Online News/Reports/Publications434

Genomics Precision Health (GPH): The use of pathogen and human genomics and advanced molecular detection methods in discovery, clinical and public health investigations and response to COVID-19.
Non Genomics Precision Health (non-GPH): The use of big data, data science, digital health, machine learning and predictive analytic methods (not involving genomics) in discovery, clinical and public health investigations and response to COVID-19

Following categories are annotated by LitCovid from NCBI NIH.
MechanismUnderlying cause(s) of covid-19 infections and transmission & possible drug mechanism of action
Transmission Characteristics and modes of covid-19 transmissions, such as human-to-human
DiagnosisDisease assessment through symptoms, test results, and radiological features
PreventionPrevention, control, response and management strategies
Case ReportDescriptions of specific patient cases
ForecastingModelling and estimating the trend of covid-19 spread

Following categories are annotated by the text mining tool from CDC PHGKB
Health EquityRelevant to health equity. Search terms are derived from a list provided by the Association for Territorial Health Officials which include terms such as diversity, health disparities, and others.
VaccineRelevant to vaccine development, evaluation, implementation and impact. For additional information on vaccines and COVID-19. Check out general CDC Information pages
VariantRelevant to SARS-CoV-2 variants and their impact on public health. For additional information on variants COVID-19. Check out CDC New Variants of the Virus that Causes COVID-19 page
SurveillanceRelevant to SARS-CoV-2 public health surveillance and tracking. For additional information on COVID-19 surveillance, check out CDC COVID-19 Data Tracker

Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Genomics and Precision Public Health to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.